* Free cash flow = OCF − net investing outflow (the filings carry no standalone capex line).
Dividends declared (per SOCE filings): FY2022 0 · FY2023 560 · FY2024 2,200 — 3-yr total 2,760
Georgian distribution arm of Berlin-Chemie/Menarini, the Italian-German pharmaceutical group, marketing its prescription medicines locally.
Subsidiary of Shezghuduli Pasukhismgeblobis Sazogadoeba Berlin Hemi 72445 Distribushens (100.0%)
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | CAGR |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 9,025 | 32,888 | 46,877 | 50,100 | 43,284 | 50,523 | 72,981 | +41.7% |
| Total COGS | 6,196 | 21,286 | 28,541 | 34,788 | 28,660 | 38,343 | 65,429 | +48.1% |
| Gross Profit | 2,829 | 11,602 | 18,336 | 15,312 | 14,624 | 12,180 | 7,552 | +17.8% |
| Gross Margin | 31.3% | 35.3% | 39.1% | 30.6% | 33.8% | 24.1% | 10.3% | |
| Other Operating Income | 0 | 0 | 0 | 0 | 652 | 11 | 2 | nmf |
| 3,031 | 10,323 | 11,069 | 12,874 | 13,382 | 10,258 | 4,935 | +8.5% | |
| EBITDA | 202 | 1,279 | 7,267 | 2,438 | 1,894 | 1,933 | 2,619 | nmf |
| EBITDA Margin | 2.2% | 3.9% | 15.5% | 4.9% | 4.4% | 3.8% | 3.6% | |
| Total D&A | 51 | 208 | 316 | 379 | 299 | 245 | 119 | +15.2% |
| EBIT / Operating Income | 253 | 1,071 | 6,951 | 2,059 | 1,595 | 1,688 | 2,500 | nmf |
| Total Interest Expense | 155 | 542 | 878 | 636 | 919 | 89 | 278 | +10.2% |
| Total Other Income | 40 | 331 | 368 | 591 | 0 | 0 | 0 | +145.4% |
| Profit Before Tax | 368 | 860 | 6,441 | 2,014 | 676 | 1,599 | 2,222 | nmf |
| Total Income Tax | 0 | 0 | 0 | 0 | 0 | 99 | 388 | +291.9% |
| Net Profit / (Loss) | 389 | 810 | 6,405 | 1,953 | 591 | 1,500 | 1,834 | nmf |
| Net Margin | 4.3% | 2.5% | 13.7% | 3.9% | 1.4% | 3.0% | 2.5% |
Shareholders, directors and group links from the companyinfo.ge public register — as filed, so stakes need not sum to 100% where a holding is undisclosed.
Ownership & directors from companyinfo.ge (public corporate registry).
Ranked by how close each latest revenue is to this one — not a curated comp set.